Polycystic ovary syndrome: New approaches to treatment (A literature review)
Pankova A.N. Abenova A.S. Tleubayeva T.M. Toylybayeva M.D.
30 September 2025Kaz Med Print LLP
Reproductive Medicine (Central Asia)
2025#2025Issue 393 - 101 pp.
Relevance: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age, leading to hormonal imbalances, metabolic issues, and difficulties with ovulation. This article reviews the latest research since 2020, with a focus on diagnosing, pathogenesis, and modern treatment methods for PCOS. Particular attention is given to new therapeutic approaches, including glucagon-like peptide-1 (GLP-1) receptor agonists, antiandrogens, and nonsteroidal anti-inflammatory drugs (NSAIDs). The article discusses findings that support the effectiveness of these treatments and their roles in improving insulin resistance, reducing hyperandrogenism, and decreasing inflammatory processes. The study aimed to analyze modern approaches to diagnosing, treating, and preventing polycystic ovary syndrome based on current scientific literature. Materials and Methods: The review includes sources from PubMed and Google Scholar. Studies published over the past seven years were selected, with an emphasis on clinical guidelines, meta-analyses, and systematic reviews. Epidemiological and molecular aspects of PCOS pathogenesis were also examined. Results: The current diagnostic criteria for PCOS, adopted in Rotterdam in 2003, include two of the following three features: ovarian cysts, hyperandrogenism, and ovulatory dysfunction. However, recent studies have highlighted the need to revise these criteria. In particular, studies from 2021 have shown that some patients with significant hyperandrogenism and anovulation may not present with cysts, suggesting the need for a more in-depth analysis of hormonal and genetic profiles. Conclusion: PCOS remains a relevant medical and scientific challenge. Recent studies have revealed new aspects of its pathogenesis, including genetic, metabolic, and inflammatory factors, which enable more accurate therapy selection and the development of preventive strategies. Continued research in this field is crucial for developing more effective and safer treatment methods and enhancing the quality of life for patients with PCOS.
antiandrogens , glucagon-like peptide-1 (GLP-1) receptor agonists , Polycystic ovary syndrome (PCOS)
Text of the article Перейти на текст статьи
Department of Obstetrics and Gynecology (including Pediatric Gynecology), Karaganda Medical University, Karaganda, Kazakhstan
Department of Obstetrics, Gynecology and Perinatology, Karaganda Medical University, Karaganda, Kazakhstan
Department of Obstetrics and Gynecology (including Pediatric Gynecology)
Department of Obstetrics
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026